The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantl...

por Kamil D. Kaplanov
Publicado 2021

ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia

por Tatiana E. Bialik, Vladimir I. Vorob'ev, Valerii A. Ionin, Loic Ysebaert, Kamil D. Kaplanov, Larisa P. Mendeleeva, Evgenii A. Nikitin, Vadim V. Ptushkin, Olga S. Samoilova, Elena A. Stadnik
Publicado 2021

New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas

por Irina V. Poddubnaya, Vadim V. Ptushkin, Irena E. Belousova, L. G. Gorenkova, Kamil D. Kaplanov, A. E. Karamova, Alla M. Kovrigina, O. A. Kolomeitsev, T. S. Konstantinova, Muza M. Kokhan, Tatyana I. Pospelova
Publicado 2020

ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

por Irina V. Poddubnaya, Lyubov S. Al-Radi, Tatyana E. Byalik, Kamil D. Kaplanov, Valentina Z. Molostvova, Evgeniy A. Nikitin, Tatyana I. Pospelova, Vadim V. Ptushkin, Olga S. Samoilova, Elena A. Stadnik, Gayane S. Tumyan
Publicado 2020

Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas

por Irina V. Poddubnaya, Elena A. Bariakh, Sergei V. Voloshin, Liliia G. Gorenkova, Kamil D. Kaplanov, Alla M. Kovrigina, Nataliia B. Mikhailova, Tatiana I. Pospelova, Vadim V. Ptushkin, Gaiane S. Tumian, Natalia A. Falaleeva, Gulnara N. Khusainova
Publicado 2021